Clinical Trial: CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053462) titled 'CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk' on June 08.

Brief Summary: This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection. Donor kidney grafts will have key human leukocyte antigen (HLA) genes disrupted - specifically, knockout of HLA class I heavy chains HLA-A and HLA-B, along with disabling HLA class II expression by targeting the CIITA gene (a master regulator of HLA-DR/DQ/DP). Approximately 90 adult end-stage renal disease patients will receive a CRISPR-edited do...